核苷(酸)类似物抗病毒治疗慢性乙型肝炎的优化策略

庄辉; 翁心华

核苷(酸)类似物抗病毒治疗慢性乙型肝炎的优化策略

庄辉,
翁心华

详细信息

中图分类号: R512.62
计量
- 文章访问数: 250
- HTML全文浏览量: 15
- PDF下载量: 253
- 被引次数: 0
出版历程
- 出版日期: 2011-04-20

Optimal strategy for chronic hepatitis B patients receiving nucleos (t) ide analogue antiviral treatment

摘要

摘要: <正>目前我国有4种核苷(酸)类似物可用于慢性乙型肝炎的抗病毒治疗,即拉米夫定、阿德福韦酯、恩替卡韦和替比夫定。但由于患者的性别、年龄、遗传背景、感染乙型肝炎病毒(HBV)的途径、病毒基因型、病程长短、肝脏病变程度和对治疗药物敏感性等不同,即使有同样治疗适应证的患者按同样的规范方案治疗后,仍有
- 肝炎,乙型,慢性 /
- 优化治疗 /
- 路线图 /
- 核苷(酸)类似物
- hepatitis B /
- chronic /
- optimal treatment /
- roadmap

HTML全文

参考文献(19)

[1]Lai CL, Gane E, Liaw YF, et al.Telbivudine versus lamivudinein patients with chronic hepatitis B[J].N EngI J Med, 2007, 357 (25) :2576-2588.

[2]Yuen MF, Lai CL.Telbivudine for chronic hepatitis B:theGLOBE trial[J].Future Virol, 2008, 3 (4) :317-323.

[3]Liaw YF.On-treatment outcome prediction and adjustmentduring chronic hepatitis B therapy:now and future[J].AntivirTher, 2009, 14 (10) :13-22.

[4]Keeffe EB, Dieterich DT, Han SH, et al.A treatment algorithmfor the management of chronic hepatitis B virus infectionin the United States:2008 update[J].Clin GastroenterolHepatol, 2008, 6 (12) :1315-1341.

[5]Chinese Society of Hepatology of Chinese MedicalAssociation, Chinese Society of Infectious Diseases ofChinese Medical Association.The guideline of preventionand treatment for chronic hepatitis B (2010 version) [J].Zhongguo Bingdubing Zazhi, 2011, 19 (1) :13-24.

[6]European Association for the Study of the Liver.EASL clinicalpractice guidelines:management of chronic hepatitis B[J].JHepatol, 2009, 50 (2) :227-242.

[7]Chae HB, Hann HW.Baseline HBV DNA levels is the mostimportant factor associated with virology breakthroughin chronic hepatitis B treated with lamivudine[J].World JGastroenterol, 2007, 13 (30) :4085-4090.

[8]Liaw YF, Gane E, Leung N, et al.2-year GLOBE trial results:telbivudine is superior to lamivudine in patients with chronichepatitis B[J].Gastroenterology, 2009, 136 (2) :486-495.

[9]Zeuzem S, Gane E, Liaw YF, et al.Baseline characteristicsand early on-treatment response predict the outcomes of2 years of telbivudine treatment of chronic hepatitis B[J].JHepatol, 2009, 51 (1) :11-20.

[10]Gauthier J, Bourne M, Lutz MW, et al.Quantization of hepatitis viremia and emergence of YMDD variants in patientswith chronic hepatitis B treated with lamivudine[J].J InfectDis, 1999, 180 (6) :1757-1762.

[11]Gallego A, Sheldon J, Garcia-Samaniego J, et al.Evaluationof initial virological response to adefovir and development ofadefovir-resistant mutations in patients with chronic hepatitisB[J].J Viral Hepat, 2008, 15 (5) :392-398.

[12]Yuen MF.On-treatment outcome prediction and adjustmentduring chronic hepatitis B threapy:now and future[J].Antiviral Ther, 2009, 14 (1) :13-22.

[13]Hsu CW, Chen YC, Liaw YF, et al.Prolonged efficacy andsafety of 3 years of continuous telbivudine treatment inpooled data from GLOBE and 015 study in chronic hepatitisB patients[J].J Hepatol, 2009, 50 (Suppl 1) :S331.

[14]Jia JD, Gane E.Prolonged efficacy and safety of 4 yearscontinuous telbivudine treatment in chronic hepatitis B (CHB) patients from GLOBE and 015 studies[J].Hepatol Int, 2010, 4 (Suppl 1) :56.FP 090.

[15]Yuen MF, Fung J, Seto WK, et al.Combination of baselineparameters and on-treatment hepatitis B virus DNA levels tostart and continue patients with lamivudine therapy[J].AntivirTher, 2009, 14 (5) :679-685.

[16]Chinese Telbivudine Roadmap Expert Group.Chineseroadmap for management of chronic hepatitis B patientsreceiving Telbivudine treatment[J].Zhonghua ChuanranbingZazhi, 2008, 26 (5) :257-259.

[17]Dong N, He B, Zhuang H.An online questionnaire surveyon awareness of antiviral treatment in patients with chronichepatitis B[J].Ganzang, 2009, 14 (1) :8-10.

[18]Wang L, Liu F, Liu YD, et al.Stringent cessation criterionresults in better durability of lamivudine treatment:aprospective clinical study in hepatitis B e antigen-positivechronic hepatitis B patients[J].J Viral Hepat, 2010, 17 (4) :298-304.

[19]Cai W, Xie Q, An BY, et al.On-treatment serum HBsAg levelis predictive of sustained off-treatment virologic responseto telbivudine in HBeAg-positive chronic hepatitis Bpatients[J].J Clin Virol, 2010, 48 (1) :22-26.

施引文献

资源附件(0)

访问统计